The standard practice of a 6-8 cycle chemotherapy induction followed by maintenance wasn't a deliberate trial design. It evolved organically from patient intolerance to cumulative toxicities like neuropathy, a limitation newer, less toxic drugs like TDXD don't necessarily share.

The JCOG 1008 trial exclusively studied cisplatin-eligible patients. Therefore, the weekly regimen should be seen as an alternative schedule for those who can tolerate cisplatin, not as a less toxic option to enable treatment for patients who are truly ineligible due to poor renal function, hearing loss, or other comorbidities.

Instead of starting all three drugs in a triplet combination simultaneously, a more effective clinical approach is to introduce them sequentially. By starting one drug, then adding the second, and finally the third over a period of weeks or months, clinicians can more easily identify the source of any toxicities, leading to better management and improved patient compliance.

For patients over 75 with metastatic gastric cancer, a common practice is to reduce the oxaliplatin dose from 85 to 65 mg/m² and universally omit the 5-FU bolus from the FOLFOX regimen. This pragmatic approach aims to maintain efficacy while minimizing toxicity in a more vulnerable population.

The next frontier in CSCC isn't just about new drugs, but about optimizing existing ones. A key research area is determining the minimum number of immunotherapy doses required for an optimal response—potentially just one or two—to limit toxicity, reduce treatment burden, and personalize care for high-risk patients.

Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.

In the JCOG 1008 trial, the weekly cisplatin arm had better outcomes despite a lower total drug dose. This suggests that maintaining consistent drug levels for radiosensitization throughout radiation is potentially more critical than the overall cumulative dose, which was higher in the less effective three-weekly arm.

As a practical standard of care for elderly patients, one clinician universally avoids the 5-FU bolus in metastatic settings and reduces the oxaliplatin dose in the FOLFOX regimen from 85 mg/m² to 65 mg/m² for most patients over age 75. This adjustment balances efficacy with improved tolerability in a more vulnerable population.

As survival times for metastatic gastric cancer patients extend, managing long-term toxicity is paramount. Clinicians typically administer only 6-8 cycles of oxaliplatin to prevent severe, cumulative peripheral neuropathy, allowing for longer, better-tolerated maintenance therapy with biologics.